Golden State Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Golden State Wealth Management's BMY Position: Q2 2026 in Review
Golden State Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 0.13% in Q2 2026, buying an estimated $230 and bringing the position to 3,040 shares worth $175K. The position accounts for 0.02% of the portfolio, ranked #439.
Golden State Wealth Management first reported a position in BMY in Q1 2019 and has held it in 17 quarters since. The position peaked at $330K in Q4 2020. 831 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Golden State Wealth Management held 3,040 shares of Bristol-Myers Squibb worth $175K as of Q2 2026.
- Golden State Wealth Management bought 4 Bristol-Myers Squibb shares in Q2 2026, an estimated $230.
- Bristol-Myers Squibb made up 0.02% of Golden State Wealth Management's portfolio in Q2 2026, its #439 holding.
- Golden State Wealth Management first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 17 quarters since.
- Golden State Wealth Management's Bristol-Myers Squibb position peaked at $330K in Q4 2020.
- 831 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.